Registry for children with Noonan syndrome on growth hormone
Part of Bones, joints & muscles, Genetic & congenital, Heart & circulation, Skin clinical trials.
This trial is a real-world registry that collects information about children with Noonan syndrome who are treated with Norditropin (a growth hormone). It helps researchers understand how these children do over time in routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a diagnosis of Noonan syndrome (by doctor and/or genetic testing).
- Your child is receiving Norditropin already or is starting it soon.
- Your care team is part of the participating treatment centers.
- You, your child’s parent/guardian (LAR), and the treating doctor agree to use Norditropin before enrolling in the registry.
- You must agree to let the study team collect and use your child’s medical data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, vosoritide, to help children with Noonan syndrome who are still growing but are shorter than expected despite growth hormone treatment. It aims to see if the drug can improve their growth.
This study collects biological samples to better understand what causes Noonan syndrome. If you qualify, your participation could help researchers learn how the condition works and guide future care.
This study looks at whether people with Noonan syndrome have unusual bleeding or blood clotting problems. It aims to better understand these issues so doctors can offer better care.
This trial tests a new growth hormone medicine (GB06) for children whose bodies don't make enough growth hormone naturally. The study will see if this treatment helps children grow taller over time.
This study looks at whether consistently taking growth hormone (Norditropin) helps children reach a height goal by “near final height.” It focuses on children who are short due to growth hormone deficiency or born small for gestational age.
This study tests a new growth hormone treatment called GenSci134 for children who have not yet gone through puberty and are not growing because their bodies do not make enough growth hormone. The goal is to see if the medicine helps them grow taller.
Hear when a new Noonan Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.